Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012
Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.CNS drugs · 2022Pooled it
- Dose-response relationships of psilocybin-induced subjective experiences in humans.Journal of psychopharmacology (Oxford, England) · 2021Pooled it
- Improving Prognostic Accuracy in Subjects at Clinical High Risk for Psychosis: Systematic Review of Predictive Models and Meta-analytical Sequential Testing Simulation.Schizophrenia bulletin · 2017Pooled it
- Trial
- Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans.Journal of psychiatry & neuroscience : JPN · 2017Trial
- Oscillatory underpinnings of mismatch negativity and their relationship with cognitive function in patients with schizophrenia.PloS one · 2013Trial
- Intact neurophysiological markers of death denial in long-term ayahuasca users.Psychopharmacology · 2026Article
- Learning as the unifying mechanism of psychedelic action.Journal of psychopharmacology (Oxford, England) · 2026Review
- The serotonergic psychedelic DOI impairs deviance detection in the auditory cortex.Journal of neurophysiology · 2025Article
- The serotonergic psychedelic DOI impairs deviance detection in the auditory cortex.bioRxiv : the preprint server for biology · 2024Article
- Effects of psychedelic, DOI, on nucleus accumbens dopamine signaling to predictable rewards and cues in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Article
- Synthetic surprise as the foundation of the psychedelic experience.Neuroscience and biobehavioral reviews · 2024Review
- Psilocybin's effects on cognition and creativity: A scoping review.Journal of psychopharmacology (Oxford, England) · 2023Article
- Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.Neuropharmacology · 2023Review
- Opposite Modulation of the NMDA Receptor by Glycine and S-Ketamine and the Effects on Resting State EEG Gamma Activity: New Insights into the Glutamate Hypothesis of Schizophrenia.International journal of molecular sciences · 2023Article
- Body mass index (BMI) does not predict responses to psilocybin.Journal of psychopharmacology (Oxford, England) · 2023Article
- Suicide prevention and ketamine: insights from computational modeling.Frontiers in psychiatry · 2023Review
- Atypical prediction error learning is associated with prodromal symptoms in individuals at clinical high risk for psychosis.Schizophrenia (Heidelberg, Germany) · 2022Article
- The Altered States Database: Psychometric data from a systematic literature review.Scientific data · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Psychotomimetics like the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine and the 5-hydroxytryptamine2A receptor (5-HT(2A)R) agonist psilocybin induce psychotic symptoms in healthy volunteers that resemble those of schizophrenia. Recent theories of psychosis posit that aberrant encoding of prediction errors (PE) may underlie the expression of psychotic symptoms. This study used a roving mismatch negativity (MMN) paradigm to investigate whether the encoding of PE is affected by pharmacological manipulation of NMDAR or 5-HT(2A)R, and whether the encoding of PE under placebo can be used to predict drug-induced symptoms. Using a double-blind within-subject placebo-controlled design, S-ketamine and psilocybin, respectively, were administrated to two groups of healthy subjects. Psychological alterations were assessed using a revised version of the Altered States of Consciousness (ASC-R) questionnaire. As an index of PE, we computed changes in MMN amplitudes as a function of the number of preceding standards (MMN memory trace effect) during a roving paradigm. S-ketamine, but not psilocybin, disrupted PE processing as expressed by a frontally disrupted MMN memory trace effect. Although both drugs produced positive-like symptoms, the extent of PE processing under placebo only correlated significantly with the severity of cognitive impairments induced by S-ketamine. Our results suggest that the NMDAR, but not the 5-HT(2A)R system, is implicated in PE processing during the MMN paradigm, and that aberrant PE signaling may contribute to the formation of cognitive impairments. The assessment of the MMN memory trace in schizophrenia may allow detecting early phases of the illness and might also serve to assess the efficacy of novel pharmacological treatments, in particular of cognitive impairments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.